Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeAdvancedLatest Governance (2026-06-29): "Restated"

Internal Control Audits by the Group Audit Department

First written in FY2023. 2 of 4 entries say "Advanced", first in FY2024. Latest entry: 2026-06-29.

4entries
4years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023AdvancedFY2024 – FY20252023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Coordination among Internal, Quality, Information Systems, and Environmental AuditsA theme 3 companies write about · 0 as a headwind · 3 as a tailwind

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-06-29RestatedGovernance

    「All corporate divisions, the divisions of Group subsidiaries and the Group Corporate Planning Department undergo regular audits by the internal audit function, the Group Audit Department, concerning the operation of their internal information-disclosure systems.」

    The company reconfirmed that the Group Audit Department regularly audits the operation of internal information-disclosure systems.
  2. FY2025AdvancedAnnual report

    「当社の内部監査および財務報告に係る内部統制の評価について、グループ監査部員8名(うち、1名は公認内部監査人(CIA)の有資格者)が各規程に則り監査を行っております。」

    グループ監査部の監査体制が、前回記載の6名から8名へ拡充され、うち1名がCIA資格を有することを記載した。
  3. FY2024AdvancedAnnual report

    「当社の内部監査および財務報告に係る内部統制の評価について、グループ監査部員6名が各規程に則り監査を行っております。」

    独立したグループ監査部について、6名体制で内部監査・財務報告に係る内部統制評価を実施し、監査役・経営会議等に報告している。
  4. FY2023First statedAnnual report

    「通常の業務担当部門から独立したグループ監査部を設置し、業務活動の合理性、効率性、適正性を諸規程に準拠して評価し、不正、誤謬の廃絶ならびに業務の改善に資することとしております。」

    通常業務部門から独立したグループ監査部による業務・品質・環境分野の監査と改善確認を初めて個別テーマとして記載している。
Moved together

"Overseas Business Expansion Focused on Asia" moved the same way as this thread, in the same document, in 2 of its 4 moves.

222222★123456
  1. ★This thread
  2. 1Overseas Business Expansion Focused on Asia2×
  3. 2FY2025 Sales and Profitability Targets and the Vision of a Total Healthcare Company2×
  4. 3CO2 Emissions Reduction and Energy-Saving Targets2×
  5. 4Strengthening Group Governance and Establishing Unified Policies2×
  6. 5Development and Launch of a Hair Hormone Measurement Kit2×
  7. 6Reviewing the Rationale for Cross-Shareholdings and Selling Them2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Governance of 2026-06-29: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.